Evaluation of emotional disorders before and during treatment with interferon beta in patients with multiple sclerosis

JOURNAL OF THE NEUROLOGICAL SCIENCES

卷:413

Article

Ouallet, Jean-Christophe¹  Radat, Francoise¹  Creange, Alain²  Abdellaoui, Mohamed²  Heinzlef, Olivier³  Giannesini, Claire⁴  Hautecoeur, Patrick⁵  Hamel, Delphine Lamargue¹  Deloire, Mathilde¹  Brochet, Bruno^1,6  Deleglise, Anne-Sophie Jean⁷  Lehert, Philippe^8,9 

[1] Ctr Hosp Univ CHU Bordeaux, Serv Neurol, Bordeaux, France

[2] Univ Paris Est Creteil, Grp Hosp Henri Mondor, AP HP, Serv Neurol, Creteil, France

[3] Ctr Hosp Poissy, Serv Neurol, Poissy, France

[4] Ctr Hosp Univ St Antoine, AP HP, Serv Neurol, Paris, France

[5] Univ Catholique Lille, Serv Neurol, Lomme Les Lille, France

[6] Univ Bordeaux, NeuroCtr Magendie, INSERM U862, Bordeaux, France

[7] MerckSerono, Lyon, France

[8] Louvain Univ, Fac Econ, Louvain La Neuve, Belgium

[9] Univ Melbourne, Fac Med, Melbourne, Vic, Australia

关键词: Interferons;    Emotions;    Affective symptoms;    Depression;    Multiple sclerosis;   

DOI  :  10.1016/j.jns.2020.116739

来源: Elsevier

【 摘 要 】

Background: Domains encompassing emotional disorders in relapsing-remitting MS (RRMS) patients are still unclear. Methods: We performed a 24-month, multicenter, single-arm, prospective study. RRMS patients started IFN-beta treatment at baseline. The primary endpoint was lack of emotional control, measured using the Echelle d'HumeurDepressive (EHD) scale three times at baseline and at 10 post-treatment visits. Secondary endpoints were emotional blunting, irritability, fatigue, depression and anxiety. A linear mixed covariance model assessed change from baseline on an intention-to-treat basis, under the assumption of no mood disorder effect (one-sided 97.5% level), in which autoregressive type of autocorrelation was tested. Results: Out of 79 recruited patients, 70 were analyzed: 80% female; mean (SD) age, 37.0 (11.5) years. Mean (SD) lack of emotional control score at baseline and Month 24 was 12.7 (4.4) and 12.6 (5.5), respectively, versus 10.1 (3.2) in a healthy control population matched for age and sex. Stepwise analysis identified younger age, male sex and antidepressant use as significant predictors of higher lack of emotional control values. Conclusions: Based on 24 months of prospective follow-up, the results of this study highlights a broad spectrum of emotional disorders in the MS population at the time of disease modifying drugs initiation but no major IFN-beta-related emotional disorders (mood dyscontrol, anxiety, depression) were observed. However, sporadic occurrences of severe mood disorders and suicidality cannot be excluded.

【 授权许可】

Free